InvestorsObserver
×
News Home

How Will the Market React to Reata Pharmaceuticals Inc (RETA) Stock Getting a Bullish Rating

Friday, September 22, 2023 12:27 PM | InvestorsObserver Analysts

Mentioned in this article

How Will the Market React to Reata Pharmaceuticals Inc (RETA) Stock Getting a Bullish Rating

Reata Pharmaceuticals Inc (RETA) stock is higher by 0.17% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Reata Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on RETA!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With RETA Stock Today?

Reata Pharmaceuticals Inc (RETA) stock is trading at $172.29 as of 12:10 PM on Friday, Sep 22, a rise of $0.12, or 0.07% from the previous closing price of $172.17. Volume today is light. So far 289,121 shares have traded compared to average volume of 738,200 shares. The stock has traded between $172.25 and $172.34 so far today. To screen for more stocks like Reata Pharmaceuticals Inc click here.

More About Reata Pharmaceuticals Inc

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others. Click Here to get the full Stock Report for Reata Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App